Rexgenero is a leading regenerative medicine company and developer of advanced cell-based therapeutics for the treatment of serious diseases that are poorly treated with existing therapies. We are conducting clinical trials with our cellular therapies with the intention of obtaining marketing authorization in Europe the United States and other markets.
Cellular therapies have the potential to successfully treat serious vascular, neurological and other disorders. Rexgenero’s technologies engineer naturally occurring stem cells to regenerate diseased tissues. In our clinical programs we are investigating the effectiveness of our therapies in diabetic and non-diabetic patients with peripheral arterial disease and associated critical limb ischemia (CLI).
Our clinical candidate therapies use three different cellular technologies: bone marrow-derived mononuclear cells (BM-MNC), adipose derived mesenchymal stem cells (MSC) and bone marrow-derived CD133+ cells.
Our therapies have the potential to alleviate debilitating symptoms including intractable pain and non-healing ulcers and also address the underlying loss of blood vessels and tissue ischemia. Our therapies have the potential to be effective even in patients where manual revascularisation is not possible and the inability to alleviate symptoms effectively is traumatic for the patient, often leads to amputation and is very costly for the health care system.